% of Cases treated with Chemotherapy
Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
---|---|---|---|---|---|---|
All invasive xnmsc | 25.6% | 25.0% | 25.9% | 22.0% | 25.5% | 26.8% |
All xnmsc 0-24 | 64.9% | 59.5% | 66.1% | 59.8% | 53.7% | 58.1% |
All xnmsc 25-59 | 40.5% | 41.6% | 40.2% | 39.8% | 41.4% | 45.0% |
All xnmsc 60-79 | 26.0% | 25.1% | 26.5% | 21.0% | 25.4% | 27.4% |
All xnmsc 80+ | 7.8% | 6.4% | 8.2% | 4.4% | 6.0% | 7.1% |
Haematology | 52.2% | 49.6% | 52.6% | 50.7% | 43.9% | 51.2% |
Head and Neck | 28.7% | 26.7% | 29.3% | 23.5% | 20.6% | 33.4% |
Lower GI | 30.8% | 31.2% | 31.0% | 26.3% | 34.2% | 33.3% |
Upper GI | 38.2% | 38.0% | 38.5% | 34.0% | 40.3% | 39.1% |
HPB | 23.4% | 21.2% | 24.2% | 16.6% | 23.4% | 20.8% |
Trachea, Bronchus & Lung | 22.4% | 22.0% | 23.1% | 15.0% | 24.2% | 25.7% |
Melanoma of skin | 3.8% | 3.9% | 3.9% | 0.5% | 4.0% | 7.4% |
Breast | 32.5% | 32.6% | 32.4% | 31.7% | 31.8% | 34.5% |
Cervix | 39.6% | 41.5% | 38.9% | 44.7% | 42.5% | 40.0% |
Other Female Genitals | 29.2% | 27.3% | 29.5% | 29.5% | 24.5% | 25.5% |
Prostate | 5.6% | 6.2% | 5.6% | 2.2% | 8.2% | 8.9% |
Kidney | 9.3% | 10.8% | 9.3% | 4.2% | 12.8% | 16.7% |
Bladder | 26.6% | 27.5% | 26.7% | 22.6% | 28.9% | 31.7% |
Brain and CNS | 35.0% | 32.1% | 35.5% | 35.3% | 28.2% | 29.6% |
Thyroid & other endocrine glands | 3.4% | 7.3% | 2.9% | 4.4% | 3.8% | 18.2% |
CUP | 7.9% | 9.3% | 7.9% | 8.8% | 15.5% | 5.2% |
Other invasive cancer | 26.5% | 26.1% | 26.6% | 24.7% | 26.7% | 26.4% |
Breast in situ | 1.7% | 1.8% | 1.7% | 0.3% | 4.6% | 0.4% |
Cervix in situ | 0.0% | 0.1% | 0.0% | 0.0% | 0.3% | 0.0% |
Other tumours | 12.2% | 10.2% | 12.5% | 14.1% | 4.4% | 9.9% |
Non-Melanoma Skin Cancer | 0.2% | 0.5% | 0.1% | 0.9% | 1.0% | 0.1% |